Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) Products under Development by Stage of Development | 7 | 1 |
| 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) Products under Development by Therapy Area | 8 | 1 |
| 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) Products under Development by Indication | 9 | 1 |
| 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) Products under Development by Companies | 12 | 2 |
| 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) Products under Development by Universities/Institutes | 14 | 2 |
| 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) Therapeutics Assessment | 16 | 5 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Route of Administration | 17 | 2 |
| Assessment by Molecule Type | 19 | 2 |
| 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) Companies Involved in Therapeutics Development | 21 | 5 |
| Astellas Pharma Inc. | 21 | 1 |
| Atara Biotherapeutics, Inc. | 22 | 1 |
| Immunomic Therapeutics, Inc. | 23 | 1 |
| Vakzine Projekt Management GmbH | 24 | 1 |
| Vical Incorporated | 25 | 1 |
| 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) Drug Profiles | 26 | 14 |
| Anti-IL-2R Monoclonal Antibody + LAMP-pp65 Dendritic Cell Vaccine Drug Profile | 26 | 2 |
| ASP-0113 Drug Profile | 28 | 3 |
| Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections Drug Profile | 31 | 2 |
| Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections Drug Profile | 33 | 1 |
| CyMVectin Drug Profile | 34 | 2 |
| Cytomegalovirus vaccine 1 Drug Profile | 36 | 2 |
| pp65 DC + Td Drug Profile | 38 | 1 |
| VPM-2001 Drug Profile | 39 | 1 |
| 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) Dormant Projects | 40 | 1 |
| 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) Discontinued Products | 41 | 1 |
| 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) Featured News &Press Releases | 42 | 9 |
| Dec 06, 2015: Atara Bio Announces Positive Results From a Phase 2 Clinical Trial of Cytomegalovirus Targeted Cytotoxic T Lymphocytes, a Novel Approach to Adoptive Immunotherapy, to Treat Patients With Refractory CMV Disease in the Central Nervous System | 42 | 1 |
| Nov 05, 2015: Atara Bio to Present Data on CMV-CTL at the American Society of Hematology Annual Meeting 2015 | 42 | 1 |
| May 21, 2015: Vical Announces Completion of Enrollment in Phase 2 Clinical Trial of Investigational CMV Vaccine in Kidney Transplant Recipients | 43 | 1 |
| Apr 21, 2015: Vical Announces Presentation of Preclinical Data for Congenital CMV DNA Vaccine at International Conference | 44 | 1 |
| Dec 10, 2013: Astellas and Vical Announce Initiation of Phase 2 Trial of ASP0113, a Cytomegalovirus Vaccine, in Solid Organ Transplant Recipients | 44 | 1 |
| Jun 25, 2013: Vical And Astellas Initiate Phase III Trial Of ASP0113 Cytomegalovirus Vaccine | 45 | 1 |
| Apr 02, 2012: Astellas And Vical Advance Toward Phase III Trial Of TransVax CMV Vaccine Triggering $10m Milestone Payment To Vical | 45 | 1 |
| Jan 11, 2012: Vical Provides Update On CyMVectin Prophylactic Vaccine | 46 | 1 |
| Jan 11, 2012: Vical Announces Online Publication Of Phase II Proof-Of-Concept Trial Results Of TransVax | 46 | 1 |
| Jul 14, 2011: Vical Announces Scientific Advances On CyMVectin At DNA Vaccines 2011 Conference | 47 | 1 |
| Jul 14, 2011: Vical Announces Scientific Advances For TransVax At DNA Vaccines 2011 Conference | 47 | 1 |
| May 19, 2011: Vical To Present TransVax And DNA Vaccines At ASGCT Conference | 47 | 1 |
| Apr 14, 2011: Vical Receives Key European Patent For TransVax Cytomegalovirus Vaccine | 48 | 1 |
| Mar 02, 2011: Vical Receives Positive Scientific Advice From EMA For TransVax Phase III Trial | 48 | 1 |
| Sep 13, 2010: Vical Announces Positive Results From Phase II Trial Of TransVax CMV Vaccine | 49 | 2 |
| Appendix | 51 | 2 |
| Methodology | 51 | 1 |
| Coverage | 51 | 1 |
| Secondary Research | 51 | 1 |
| Primary Research | 51 | 1 |
| Expert Panel Validation | 51 | 1 |
| Contact Us | 51 | 1 |
| Disclaimer | 52 | 1 |